<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449161</url>
  </required_header>
  <id_info>
    <org_study_id>MP-31-2015-998</org_study_id>
    <nct_id>NCT02449161</nct_id>
  </id_info>
  <brief_title>The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates</brief_title>
  <acronym>MPA postAE</acronym>
  <official_title>The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates: a RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy Waddell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSSS Chicoutimi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heavy menstrual bleeding are a common reason for consultation in gynecology and are defined&#xD;
      by International Federation of Gynecology and Obstetrics as the perception of menstrual&#xD;
      volume increased regardless of the frequency, duration and regularity. Some studies report&#xD;
      that up to 30% of women will suffer from heavy periods during their lifetime. The first line&#xD;
      treatment of heavy bleeding is medical. However, a significant proportion of women require&#xD;
      surgery. Until the 80s, hysterectomy was one of the only surgical options and often performed&#xD;
      as the first line treatment. Since twenty years now the endometrial ablation has become a&#xD;
      preferred option for dysfunctional uterine bleeding and avoids hysterectomy in a significant&#xD;
      proportion of patients suffering from this type of problem. Endometrial ablation is much less&#xD;
      invasive and morbid than hysterectomy, however, many patients do not achieve a complete&#xD;
      amenorrhea with endometrial ablation and about 15% may have to require a new intervention,&#xD;
      such as hysterectomy, following the persistence of menstrual problems. A Cochrane review&#xD;
      published in 2013 showed that the satisfaction rate following endometrial ablation is high at&#xD;
      70-80% and about 35% of women have amenorrhea. The complete destruction of the endometrium is&#xD;
      the most important predictor of the success of the procedure. Studies have shown that better&#xD;
      results are obtained when the surgery is performed when the endometrium is thin or&#xD;
      immediately following menses or following administration of a hormonal agent causes atrophy&#xD;
      of the endometrium. One of the agents studied to prepare the endometrium before ablation is&#xD;
      medroxyprogesterone acetate (MPA) as injectables (DMPA) and oral. Progestins have an&#xD;
      antiproliferative effect on the endometrium. In recent years, numerous studies have examined&#xD;
      the use of various agents preoperatively, including MPA and DMPA to facilitate surgery by&#xD;
      reducing the thickness of the endometrium. However, few studies have focused on the&#xD;
      conditions of the post-operative period to promote the therapeutic response to the&#xD;
      intervention. The investigators hypothesis is whether the MPA administered in immediate&#xD;
      post-operative would inhibit proliferation of endometrial cells responsible for the&#xD;
      persistence of menstruation and optimize the clinical response to endometrial ablation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quantification of amenorrhea</measure>
    <time_frame>12 months</time_frame>
    <description>using the &quot;Pictorial Blood Loss Assessment Chart&quot; for quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantification of amenorrhea</measure>
    <time_frame>4 months</time_frame>
    <description>using the &quot;Pictorial Blood Loss Assessment Chart&quot; for quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>documentation of side effects</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>MPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 placebo/day, for 90 days, following endometrial ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPA</intervention_name>
    <arm_group_label>MPA</arm_group_label>
    <other_name>provera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  endometrial ablation planned for eavy menstrual bleeding&#xD;
&#xD;
          -  No abnormalities at hysteroscopy&#xD;
&#xD;
          -  No evidence of hyperplasia or neoplasia in endometrial biopsy&#xD;
&#xD;
          -  Hysterometry of ≤ 10 cm preoperatively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any indication against MPA&#xD;
&#xD;
          -  Intrauterine pathology causing heavy bleeding&#xD;
&#xD;
          -  hormonal treatment provided during the postoperative period (during the first 4&#xD;
             months)&#xD;
&#xD;
          -  preoperative hormonal therapy with a residual postoperative effect&#xD;
&#xD;
          -  breastfeeding&#xD;
&#xD;
          -  future pregnancy planned&#xD;
&#xD;
          -  menopausal women&#xD;
&#xD;
          -  endometrial ablation antecedent&#xD;
&#xD;
          -  Suspected pelvic infection&#xD;
&#xD;
          -  known Hematologic Disease&#xD;
&#xD;
          -  Taking anticoagulant&#xD;
&#xD;
          -  Taking progestin in the 6 months before surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Myriam Flipot, RN</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>18433</phone_ext>
    <email>mailto:myriam.flipot.ciussse-chus@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Léonie Anne Dallaire-Nantel, MD</last_name>
    <email>Leonie.Anne.Dallaire-Nantel@USherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Flipot, RN</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>18433</phone_ext>
      <email>myriam.flipot.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Guy Waddell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Guy Waddell</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>endometrial ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

